CA2671806A1 - Liberation declenchee a distance depuis des surfaces pouvant etre chauffees - Google Patents

Liberation declenchee a distance depuis des surfaces pouvant etre chauffees Download PDF

Info

Publication number
CA2671806A1
CA2671806A1 CA002671806A CA2671806A CA2671806A1 CA 2671806 A1 CA2671806 A1 CA 2671806A1 CA 002671806 A CA002671806 A CA 002671806A CA 2671806 A CA2671806 A CA 2671806A CA 2671806 A1 CA2671806 A1 CA 2671806A1
Authority
CA
Canada
Prior art keywords
conjugate
agent
thermally
agents
delivered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002671806A
Other languages
English (en)
Inventor
Austin M. Derfus
Geoffrey Von Maltzahn
Sangeeta N. Bhatia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2671806A1 publication Critical patent/CA2671806A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
CA002671806A 2006-12-08 2007-12-07 Liberation declenchee a distance depuis des surfaces pouvant etre chauffees Abandoned CA2671806A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87389706P 2006-12-08 2006-12-08
US60/873,897 2006-12-08
US96938907P 2007-08-31 2007-08-31
US60/969,389 2007-08-31
PCT/US2007/086863 WO2008073851A2 (fr) 2006-12-08 2007-12-07 Libération déclenchée à distance depuis des surfaces pouvant être chauffées

Publications (1)

Publication Number Publication Date
CA2671806A1 true CA2671806A1 (fr) 2008-06-19

Family

ID=40427804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002671806A Abandoned CA2671806A1 (fr) 2006-12-08 2007-12-07 Liberation declenchee a distance depuis des surfaces pouvant etre chauffees

Country Status (4)

Country Link
EP (1) EP2117595A2 (fr)
AU (1) AU2007333220A1 (fr)
CA (1) CA2671806A1 (fr)
WO (1) WO2008073851A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300410A (zh) * 2020-11-05 2021-02-02 云南师范大学 一种多孔结构的水凝胶复合材料及其制备与应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
EP2490723A1 (fr) * 2009-10-19 2012-08-29 University Of Louisville Research Foundation, Inc. Nanoparticules pour l'administration de médicaments
DE102009058769A1 (de) * 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
CN105132284B (zh) * 2011-05-13 2018-04-03 加利福尼亚大学董事会 用于选择性转染细胞的光热衬底
WO2014049566A2 (fr) * 2012-09-28 2014-04-03 Stellenbosch University Kit nutritionnel
CA2905999A1 (fr) 2013-03-15 2014-09-25 The Regents Of The University Of California Administration de charges a haut debit dans des cellules vivantes au moyen de plates-formes photothermiques
JP6839073B2 (ja) 2014-03-28 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 多孔質支持体上の細胞への大きなカーゴの効率的な送達
WO2019014549A1 (fr) 2017-07-14 2019-01-17 The Penn State Research Foundation Compositions et méthodes destinées à l'administration ciblée d'espèces thérapeutiques et/ou diagnostiques
CN110404084B (zh) * 2019-08-21 2020-10-23 青岛大学 一种基于dna光热熔融的纳米粒子与制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234831A1 (en) * 2000-02-05 2001-08-14 Florida State University Research Foundation Magnetoliposome composition for targeted treatment of biological tissue and associated methods
DE10224352A1 (de) * 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
US20060025713A1 (en) * 2003-05-12 2006-02-02 Alex Rosengart Magnetic particle-based therapy
DE10350248A1 (de) * 2003-10-28 2005-06-16 Magnamedics Gmbh Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik
WO2005065282A2 (fr) * 2003-12-31 2005-07-21 The Regents Of The University Of California Procedes et articles de traitement magnetique a distance de cancers et autres maladies et procedes pour faire fonctionner un tel article
WO2005109313A2 (fr) * 2004-04-29 2005-11-17 The Regents Of The University Of California Encapsulation de medicaments avec des oligonucleotides synthetiques
DE102005016873A1 (de) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
CN101242870B (zh) * 2005-08-19 2013-01-09 季诺维斯公司 适用于将生物分子输入膜封闭的细胞或细胞器或从膜封闭的细胞或细胞器输出的纳米颗粒
US20090324494A1 (en) * 2006-02-24 2009-12-31 Atgen Co., Ltd Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance
WO2007116954A2 (fr) * 2006-03-30 2007-10-18 Fujifilm Corporation Nanoparticule
US8017237B2 (en) * 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
RU2373957C2 (ru) * 2006-10-13 2009-11-27 Александр Метталинович Тишин Носитель для лекарственных средств и биологически активных веществ для лечения и диагностики и применение его для создания лекарственных средств и способа регулируемой управляемой доставки лекарственного средства или биологически активного вещества с регулируемой десорбцией его

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300410A (zh) * 2020-11-05 2021-02-02 云南师范大学 一种多孔结构的水凝胶复合材料及其制备与应用
CN112300410B (zh) * 2020-11-05 2022-07-15 云南师范大学 一种多孔结构的水凝胶复合材料及其制备与应用

Also Published As

Publication number Publication date
AU2007333220A1 (en) 2008-06-19
WO2008073851A3 (fr) 2009-05-22
EP2117595A2 (fr) 2009-11-18
WO2008073851A2 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
US20090093551A1 (en) Remotely triggered release from heatable surfaces
CA2671806A1 (fr) Liberation declenchee a distance depuis des surfaces pouvant etre chauffees
CA2648099C (fr) Systeme pour l'administration ciblee d'agents therapeutiques
US20110052697A1 (en) Aptamer-Directed Drug Delivery
US20140314864A1 (en) System for Targeted Delivery of Therapeutic Agents
US20110027172A1 (en) Drug delivery system for pharmaceuticals and radiation
US20130071329A1 (en) Theranostic delivery systems with modified surfaces
Parhi et al. Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy
US20230330273A1 (en) Magnetic nanoparticles functionalized with cathecol, production and use thereof
WO2011133925A2 (fr) Administration cytosolique photoactivée et ciblée de médicament
AU2014202199A1 (en) Delivery of nanoparticles and/or agents to cells
Quarta et al. Multilayered magnetic nanobeads for the delivery of peptides molecules triggered by intracellular proteases
Wang et al. Uptake mechanism and endosomal fate of drug-phospholipid lipid nanoparticles in subcutaneous and in situ hepatoma
Habra Investigating potential nano-and micro-drug delivery systems toward the non-invasive treatment of glioblastoma brain tumours
Joseph et al. Applications of Magnetically Modulated Systems
DEY et al. Success of Nanotherapy in the Treatment of Cancer-An Overview.
WO2019073371A1 (fr) Composition pharmaceutique comprenant des nanoparticules hybrides albumine-lipide

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121207

FZDE Dead

Effective date: 20141209